Friday, November 13, 2026

Palladium Futures Bullish Momentum With A 8% Rise In The Last 10 Sessions

ViaNews Editorial Team

November 27, 2023

Automated market report from our archive (2020–2024), published before source-traceability. How we work

Palladium Futures Bullish Momentum With A 8% Rise In The Last 10 Sessions

(VIANEWS) - Palladium (PA) has been up by 8.42% for the last 10 sessions. At 22:52 EST on Sunday, 26 November, Palladium (PA) is $1,075.50.

Volume

Today's last reported volume for Palladium is 5539, 99.99% below its average volume of 4079440059.32.

Volatility

Palladium's last week, last month's, and last quarter's current intraday variation average was a negative 0.23%, a negative 0.14%, and a positive 1.41%, respectively.

Palladium's highest amplitude of average volatility was 1.81% (last week), 1.65% (last month), and 1.41% (last quarter), respectively.

Commodity Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Palladium's commodity is considered to be overbought (>=80).

News about

  • According to DailyForex on Sunday, 26 November, "The West Texas Intermediate Crude Oil market has been all over the place during the course of the trading week, as we continue to look at the $75 level as a major support level. "
  • Crude oil forecast: quiet during holiday session - 24 November 2023. According to DailyForex on Friday, 24 November, "Looking to the West Texas Intermediate (WTI) Crude Oil market, we saw a slight downturn during Thursday's trading session, characterized by the persistently erratic behavior witnessed across global markets. "

More news about Palladium (PA).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,577 source documents archived
Query this data → isubstrate.com